Last reviewed · How we verify
NCT06172101: FIRST
Free Fat Flap In Recurrent Neurogenic Thoracic Outlet Syndrome Surgical Treatment
trial testing Free fat flap in Neurogenic Thoracic Outlet Syndrome in 20 participants. Currently enrolling.
18 May 2026
Quick facts
| Lead sponsor | Nantes University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 18 December 2023 |
| Primary completion | 18 May 2026 |
| Estimated completion | 18 May 2026 |
| Sites | 1 location across France |
Drugs / interventions tested
- Free fat flap
Conditions studied
- Neurogenic Thoracic Outlet Syndrome — all drugs for Neurogenic Thoracic Outlet Syndrome →
Sponsor
Nantes University Hospital
Who can join
18 and older, any sex, with Neurogenic Thoracic Outlet Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Thoraco-Brachial Outlet Syndrome (T-BOS) corresponds to the entirety of clinical manifestations related to the compression of the branches of the brachial plexus and/or the subclavian vessels during their passage through the cervico-thoracic region. Following surgery, a recurrence of symptoms occurs in 5% to 30% of operated patients. The treatment of these recurrences primarily relies on conservative therapies, and in case of failure, surgical intervention, particularly neurolysis of the brachial plexus. In order to prevent a new recurrence, it is desirable to cover the neurolyzed brachial plexus with a flap, providing better local vascularization. However, fatty perforating flaps, by avoiding muscle harvesting, reduce donor site sequelae. We aim to investigate, through validated and recommended questionnaires, the impact of covering the neurolyzed brachial plexus with a free fatty flap after neurolysis in the context of recurrent neurological Thoraco-Brachial Outlet Syndrome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Free fat flap transfer in recurrent neurogenic thoracic outlet syndrome pain treatment: FIRST observational pilot study.
Thuau F, Gadbled G, Goronflot T, Perrot P, et al · · 2025 · PMID 40861285 · DOI 10.1097/sp9.0000000000000045
Verify or expand the search:
- PubMed search for NCT06172101
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Nantes University Hospital trials
Trials by the same sponsor.
- NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
- NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
- NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
- NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
- NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06172101 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
- Last refreshed: 19 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06172101.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing